David van Duin

About David van Duin

David van Duin, With an exceptional h-index of 57 and a recent h-index of 46 (since 2020), a distinguished researcher at University of North Carolina at Chapel Hill, specializes in the field of Antibacterial resistance.

His recent articles reflect a diverse array of research interests and contributions to the field:

Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii

Delayed mortality among solid organ transplant recipients hospitalized for COVID-19

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in …

Reviewing novel treatment options for carbapenem-resistant Enterobacterales

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina

Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions

Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021

Carbapenem-Resistant Enterobacterales in Children at 18 US Health care system study sites: Clinical and Molecular Epidemiology from a Prospective Multicenter …

David van Duin Information

University

Position

Associate Professor of Medicine

Citations(all)

13205

Citations(since 2020)

8944

Cited By

7093

hIndex(all)

57

hIndex(since 2020)

46

i10Index(all)

118

i10Index(since 2020)

112

Email

University Profile Page

Google Scholar

David van Duin Skills & Research Interests

Antibacterial resistance

Top articles of David van Duin

Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii

2024/4/1

David Van Duin
David Van Duin

H-Index: 38

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in …

Antimicrobial agents and chemotherapy

2024/3/6

David Van Duin
David Van Duin

H-Index: 38

Yohei Doi
Yohei Doi

H-Index: 54

Reviewing novel treatment options for carbapenem-resistant Enterobacterales

2024/3/3

David Van Duin
David Van Duin

H-Index: 38

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina

Journal of Antimicrobial Chemotherapy

2024/2/21

Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions

Clinical Infectious Diseases

2024/2/15

Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021

Clinical Infectious Diseases

2024/2/2

David Van Duin
David Van Duin

H-Index: 38

Leila Ledbetter
Leila Ledbetter

H-Index: 14

Carbapenem-Resistant Enterobacterales in Children at 18 US Health care system study sites: Clinical and Molecular Epidemiology from a Prospective Multicenter …

Open Forum Infectious Diseases

2024/1/8

Matthew Fisher
Matthew Fisher

H-Index: 10

David Van Duin
David Van Duin

H-Index: 38

Impact of childhood malnutrition and intestinal microbiota on MDR infections

2023/4/1

David Van Duin
David Van Duin

H-Index: 38

Klebsiella pneumoniae clinical isolates with features of both multidrug-resistance and hypervirulence have unexpectedly low virulence

Nature communications

2023/12/2

David Van Duin
David Van Duin

H-Index: 38

Liang Chen
Liang Chen

H-Index: 8

719. Stenotrophomonas maltophilia in Japanese hospitals: Clinical characteristics and molecular epidemiology of infection and colonization cases registered in …

Open Forum Infectious Diseases

2023/12

1029. Increased Mortality in Hospital-Onset Carbapenem-Resistant Enterobacterales Bloodstream Infections

Open Forum Infectious Diseases

2023/12

Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

The Lancet Microbe

2023/3/1

Duration of antibiotic treatment for acute graft pyelonephritis: What's the standard of care?

Transplant Infectious Disease

2023/2

David Van Duin
David Van Duin

H-Index: 38

215. Shorter vs. Longer Duration of Treatment in Patients with Ceftriaxone-resistant and Ceftriaxone-susceptible Escherichia coli Bloodstream Infections

Open Forum Infectious Diseases

2023/12

Yohei Doi
Yohei Doi

H-Index: 54

David Van Duin
David Van Duin

H-Index: 38

371. Clinical Characteristics and Prognoses for Carbapenem-Resistant Bacterial Infections in Patients with Cancer in Japan: A Multicenter Study from the Multi-Drug Resistant …

Open Forum Infectious Diseases

2023/12

Transmission of Carbapenem-Resistant Klebsiella pneumoniae in US Hospitals

Clinical Infectious Diseases

2023/1/15

COVID-19 HOSPITALIZATION RISK AFTER SARS-CoV-2 VACCINATION AND OUTPATIENT TREATMENT

Topics in Antiviral Medicine

2023

170. Outcomes after Stenotrophomonas maltophilia bloodstream infection

Open Forum Infectious Diseases

2023/12

Marco Falcone
Marco Falcone

H-Index: 17

David Van Duin
David Van Duin

H-Index: 38

1806. Community Spread of Highly Resistant Enterobacterales

Open Forum Infectious Diseases

2023/12

Liang Chen
Liang Chen

H-Index: 8

David Van Duin
David Van Duin

H-Index: 38

See List of Professors in David van Duin University(University of North Carolina at Chapel Hill)

Co-Authors

academic-engine